This article discusses a case study of a patient with refractory B-cell acute lymphoblastic leukemia (B-ALL) and leukemia cutis (LC) who underwent chimeric antigen receptor T-cell (CAR-T) therapy. The study presents serial dermatopathology findings before and during CAR-T therapy, showing evidence of a cytotoxic response to treatment. The patient experienced a recrudescence of LC lesions following CAR-T therapy, which eventually resolved with supportive therapy. The study suggests that CAR-T therapy can effectively target and eliminate LC, but further research is needed to understand the long-term prognostic and predictive value of these findings. [Extracted from the article]